The pyrrolidine compound RG7388 is a second-generation MDM2 small molecular inhibitor, which blocks the physical interaction between MDM2 and p53 and is undergoing pre-clinical and clinical evaluation as a potential anti-cancer therapeutic [20]. This evidence concerns the gene MDM2 and cancer.